AGA Institute Releases Updated Guidelines on Managing Hepatitis B Reactivation
The American Gastroenterology Association (AGA) Institute has published new clinical practice guidelines aimed at managing hepatitis B reactivation (HBVr) in at-risk individuals. These guidelines offer evidence-based recommendations that emphasize the importance of antiviral prophylaxis for those at high or moderate risk.
Image credit: Rasi – stock.adobe.com
Global Impact of Chronic Hepatitis B
The World Health Organization (WHO) reports that approximately 254 million people globally were living with chronic hepatitis B (HBV) infection in 2022, with 1.2 million new cases reported annually. This underscores the significant burden of chronic HBV and the need for effective management strategies.
Hepatitis B Reactivation: A Critical Concern
Hepatitis B reactivation can occur in individuals with a history of the infection, particularly during periods of immunosuppression or exposure to immunosuppressive therapies. Research from 2023 highlights that the reactivation rate among patients who have recovered from HBV and undergone non-liver solid organ transplants is 2.5%. This makes it a significant concern in medical settings involving immunosuppression.
New Guidelines Offer Detailed Recommendations
The updated guidelines, published in Gastroenterology, refine and expand upon the 2015 AGA guidelines. They provide four key recommendations to manage HBVr risk based on patient risk levels:
- High-risk of HBVr: Antiviral prophylaxis is recommended before starting risk-imposing therapy and for 6 to 12 months after discontinuation.
- Moderate-risk of HBVr: Antiviral prophylaxis is suggested, but monitoring may be chosen based on patient preferences, with regular assessments.
- Low-risk of HBVr: Monitoring alone is preferred, but antiviral therapy can be considered for patients on multiple low-risk immunosuppressive medications.
- Patients potentially at risk of HBVr: Hepatitis B testing is recommended for all individuals at potential risk, in line with CDC screening guidelines for all adults aged 18 years and over.
Evolving Treatment Approaches
The new guidelines emphasize a more personalized approach, encouraging the consideration of patient preferences alongside clinical recommendations. By refining the recommendations for lower-risk individuals, the guidelines aim to balance clinical effectiveness with patient values.
Addressing Knowledge Gaps and Future Directions
The updated guidelines acknowledge persistent knowledge gaps in HBVr risk categorization, largely due to limited evidence and imprecise baseline risk estimates. To address these gaps, the authors advocate for the establishment and maintenance of national registries and the use of technological innovations, such as online risk repositories.
These efforts could enhance the accuracy of baseline risk estimates and improve HBVr prevention strategies in the evolving landscape of immunotherapeutics.
Emphasizing Equity and Health Disparities
The guidelines also prioritize equitable access to HBV prophylaxis, monitoring, and treatment, highlighting the importance of addressing health disparities in the management of hepatitis B reactivation.
Conclusion
The AGA Institute’s updated clinical practice guidelines offer a comprehensive and evidence-based approach to managing hepatitis B reactivation. By emphasizing personalized, risk-based management and addressing gaps in the current understanding of HBVr, these guidelines aim to improve patient outcomes and reduce the risk of reactivation in at-risk individuals.
To stay informed about the latest developments in this field, subscribe to our newsletter or follow us on social media. Your support helps us bring you the most accurate and up-to-date information on health and medical advancements.
What do you think about these new guidelines? Share your thoughts below!
